AQR Capital Management
VKTX icon

AQR Capital Management’s Viking Therapeutics VKTX Stock Holding History

AQR Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.84M Buy
200,958
+188,786
+1,551% +$6.1M ﹤0.01% 1722
2026
Q1 		$390K Buy
+12,172
New +$391K ﹤0.01% 3267
2025
Q4 		– Sell
-13,072
Closed -$334K – 3647
2025
Q3 		$334K Sell
13,072
-51,656
-80% -$1.54M ﹤0.01% 3027
2025
Q2 		$1.72M Sell
64,728
-80,391
-55% -$2.12M ﹤0.01% 1877
2025
Q1 		$3.44M Sell
145,119
-392,120
-73% -$12.4M ﹤0.01% 1318
2024
Q4 		$21.5M Buy
537,239
+73,710
+16% +$4.2M 0.03% 613
2024
Q3 		$29.1M Buy
463,529
+395,459
+581% +$23.2M 0.04% 525
2024
Q2 		$3.61M Buy
68,070
+28,180
+71% +$1.85M 0.01% 1177
2024
Q1 		$3.27M Sell
39,890
-7,569
-16% -$337K 0.01% 1187
2023
Q4 		$883K Sell
47,459
-8,204
-15% -$107K ﹤0.01% 1648
2023
Q3 		$616K Buy
55,663
+24,266
+77% +$347K ﹤0.01% 1776
2023
Q2 		$509K Buy
+31,397
New +$658K ﹤0.01% 1782
2022
Q3 		– Sell
-122,356
Closed -$354K – 2330
2022
Q2 		$354K Buy
122,356
+78,431
+179% +$194K ﹤0.01% 1803
2022
Q1 		$132K Buy
+43,925
New +$158K ﹤0.01% 2118
2019
Q3 		– Sell
-33,106
Closed -$275K – 2169
2019
Q2 		$275K Buy
33,106
+206
+0.6% +$1.76K ﹤0.01% 1901
2019
Q1 		$327K Sell
32,900
-1,256
-4% -$10.5K ﹤0.01% 1943
2018
Q4 		$261K Sell
34,156
-26,778
-44% -$320K ﹤0.01% 2004
2018
Q3 		$1.06M Sell
60,934
-18,542
-23% -$221K ﹤0.01% 1682
2018
Q2 		$754K Buy
+79,476
New +$529K ﹤0.01% 1833

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

AQR Capital Management's VKTX Position: Q2 2026 in Review

AQR Capital Management increased its Viking Therapeutics (VKTX) stake by 1,551% in Q2 2026, buying an estimated $6.1M and bringing the position to 200,958 shares worth $7.84M. The position accounts for ﹤0.01% of the portfolio, ranked #1722.

AQR Capital Management first reported a position in VKTX in Q2 2018 and has held it in 19 quarters since. The position peaked at $29.1M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • AQR Capital Management held 200,958 shares of Viking Therapeutics worth $7.84M as of Q2 2026.
  • AQR Capital Management bought 188,786 Viking Therapeutics shares in Q2 2026, an estimated $6.1M.
  • Viking Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1722 holding.
  • AQR Capital Management first reported a position in Viking Therapeutics in Q2 2018 and has held it in 19 quarters since.
  • AQR Capital Management's Viking Therapeutics position peaked at $29.1M in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.